Alltrna Announces Updates to Its Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2024
0mins
Should l Buy IONS?
Source: Newsfilter
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 69.680
Low
65.00
Averages
92.67
High
110.00
Current: 69.680
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: The US FDA has granted Priority Review to Ionis Pharmaceuticals' NDA for zilganersen, with an action date set for September 22, accelerating the drug's potential market entry for treating the rare neurological condition, Alexander disease.
- Clinical Trial Results: In a pivotal study, children and adults receiving 50 mg of zilganersen demonstrated significant stabilization in gait speed at week 61, as measured by the 10-Meter Walk Test, indicating the drug's potential clinical value in improving patient functionality compared to the control group.
- Disease Impact: Alexander disease affects 1 in 1 to 3 million people globally, characterized by loss of functional mobility and independence, as well as the inability to control large movements, swallowing, and airway protection, highlighting the severity of the condition and the urgent need for effective treatments.
- Market Outlook: Ionis Pharmaceuticals outlines a peak sales target of over $2 billion for olezarsen, with optimistic projections for 2026 driven by new launches and pipeline catalysts, further bolstering investor confidence in the company's future growth prospects.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: Ionis Pharmaceuticals announced that its New Drug Application for zilganersen, targeting Alexander disease, has been accepted for Priority Review by the FDA, with a PDUFA date set for September 22, 2026, indicating the drug's potential to be the first treatment for this condition and addressing a significant unmet need in the market.
- Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a statistically significant 33.3% improvement in gait speed at week 61 (p=0.0412), highlighting the drug's important clinical relevance in enhancing patient mobility.
- Market Potential: Alexander disease is a rare and often fatal neurological disorder, occurring in approximately 1 in 1 to 3 million people globally, and the successful launch of zilganersen would fill a critical gap in treatment options, thereby strengthening Ionis's market position in neurology.
- Strategic Milestone: If approved, zilganersen will mark Ionis's first independent commercial launch in neurology, which will not only drive growth in this sector but also support the company's strategic goal of continuously developing transformative medicines for serious diseases.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: The US FDA has granted Priority Review to Ionis Pharmaceuticals' NDA for zilganersen, with an action date set for September 22, accelerating the drug's potential market entry for treating the rare neurological condition, Alexander disease.
- Clinical Trial Results: In a pivotal study, children and adults receiving 50 mg of zilganersen demonstrated significant stabilization in gait speed at week 61, as measured by the 10-Meter Walk Test, indicating the drug's potential clinical value in improving patient functionality compared to the control group.
- Disease Impact: Alexander disease affects 1 in 1 to 3 million people globally, characterized by loss of functional mobility and independence, as well as the inability to control large movements, swallowing, and airway protection, highlighting the severity of the condition and the urgent need for effective treatments.
- Market Outlook: Ionis Pharmaceuticals outlines a peak sales target of over $2 billion for olezarsen, with optimistic projections for 2026 driven by new launches and pipeline catalysts, further bolstering investor confidence in the company's future growth prospects.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: Ionis Pharmaceuticals announced that its New Drug Application for zilganersen, targeting Alexander disease, has been accepted for Priority Review by the FDA, with a PDUFA date set for September 22, 2026, indicating the drug's potential to be the first treatment for this condition and addressing a significant unmet need in the market.
- Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a statistically significant 33.3% improvement in gait speed at week 61 (p=0.0412), highlighting the drug's important clinical relevance in enhancing patient mobility.
- Market Potential: Alexander disease is a rare and often fatal neurological disorder, occurring in approximately 1 in 1 to 3 million people globally, and the successful launch of zilganersen would fill a critical gap in treatment options, thereby strengthening Ionis's market position in neurology.
- Strategic Milestone: If approved, zilganersen will mark Ionis's first independent commercial launch in neurology, which will not only drive growth in this sector but also support the company's strategic goal of continuously developing transformative medicines for serious diseases.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
